Clinical Cancer Research CR Balducci Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, K.
Right arrow Articles by Kawaguchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, K.
Right arrow Articles by Kawaguchi, Y.
Clinical Cancer Research Vol. 6, 4409-4415, November 2000
© 2000 American Association for Cancer Research

Regular Articles

Bioactivation of Tegafur to 5-Fluorouracil Is Catalyzed by Cytochrome P-450 2A6 in Human Liver Microsomes in Vitro1

Kazumasa Ikeda, Kunihiro Yoshisue, Eiji Matsushima, Sekio Nagayama, Kaoru Kobayashi, Charles A. Tyson, Kan Chiba2 and Yasuro Kawaguchi

Pharmacokinetics Research Laboratory, Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima 771-0194, Japan [K. I., K. Y., E. M., S. N., Y. K.]; Toxicological Laboratory, SRI International, CA 94025-3493 [C. A. T.]; and Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University, Chiba 263-8522, Japan [K. K., K. C.]

ABSTRACT

Tegafur is a prodrug of 5-fluorouracil (5-FU) consisting of a new class of oral chemotherapeutic agents, tegafur/uracil and S-1, which are classified as dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. It is bioactivated to 5-FU via 5'-hydroxylation mediated by cytochrome P-450 (CYP). However, which isoform(s) of CYP is responsible for the bioactivation process of tegafur remains unclear. The purpose of the present study was to identify the human CYP isoform(s) involved in the metabolic activation of tegafur using human liver microsomes and cDNA-expressed human CYPs.

The formation of 5-FU from tegafur in human liver microsomes showed biphase kinetics with Km and Vmax values for the high-affinity component of 0.43 ± 0.05 mM and 4.02 ± 1.70 nmol/mg/min (mean ± SD, n = 4), respectively. In the correlation study using a panel of 10 human liver microsomes, the formation of 5-FU from tegafur showed a significant correlation (r = 0.98; P < 0.001) with coumarin 7-hydroxylation, a marker activity of CYP2A6. In addition, a specific substrate of CYP2A6 and anti-CYP2A6 antibody inhibited the formation of 5-FU by 90% in human liver microsomes. Moreover, cDNA-expressed CYP2A6 showed the highest activity for the formation of 5-FU among 10 cDNA-expressed CYPs, with a Km value similar to that found for the high-affinity component in human liver microsomes.

These findings clearly suggest that CYP2A6 is a principal enzyme responsible for the bioactivation process of tegafur in human liver microsomes. However, to what extent the bioactivation of tegafur by CYP2A6 accounts for the formation of 5-FU in vivo remains unclear, because the formation of 5-FU from tegafur is also catalyzed by the soluble fraction of a 100,000 x g supernatant and also derived from spontaneous degradation of tegafur.

INTRODUCTION

Tegafur is a prodrug of 5-FU3 synthesized >30 years ago (1) . Although its development was abandoned in the United States for more than two decades, it has been developed as a new class of oral chemotherapeutic agent in Japan. These new agents include tegafur/uracil and S-1, which are known as dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines (2 , 3) . They have been so classified because they are composed of 5-FU prodrug and uracil or 5-chloro-2,4-dihydroxypyridine, which prevents the degradation of 5-FU, thus ensuring that the concentration of 5-FU remains at sustained levels in both the plasma and the tumor (3 , 4) . Tegafur/uracil and S-1 have been commercially available in Japan since 1983 and 1999, respectively, and have been extensively studied for their effectiveness in treating various tumors, including colon rectal cancer (3) , gastric carcinoma (5) , pulmonary malignancy (6) , and head and neck cancer (7) . Recently, they have been subjected to clinical evaluation in the United States (2, 3, 4, 5, 6, 7) .

Tegafur is a depot form of fluorouracil, which releases 5-FU slowly in the body. The conversion of tegafur to fluorouracil mainly occurs in the liver. As illustrated in Fig. 1Citation , it is hydroxylated at the 5'-position of a furan ring to produce 5'-hydroxytegafur, which is unstable and is spontaneously decomposed to 5-FU (8) . This bioactivation process is thought to be mediated by CYP, because NADPH is required for the conversion of tegafur to 5-FU in liver microsomes (9) , and its conversion rate has been shown to be accelerated by the pretreatment of mice with phenobarbital (10) , a well-known inducer of CYP. However, which isoform(s) of CYP is responsible for the bioactivation process of tegafur remains unclear.



View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Proposed metabolic pathways of tegafur to 5-FU via CYP. Tegafur is hydroxylated by CYP to 5'-hydroxytegafur, which is unstable and spontaneously degraded to 5-FU and a succinic aldehyde moiety (8) .

 
Identification of the human isoform of CYP responsible for the metabolism of a drug is useful for assessing the interindividual variability in its metabolism, particularly when the isoform of CYP exhibits genetic polymorphism (11) . In addition, there are data available for a number of compounds that inhibit or induce specific isoforms of CYP (12) . Therefore, it will be possible to estimate the variability of metabolism or drug interactions when the specific isoform of CYP responsible for the bioactivation of tegafur in humans is identified. In this study, we identified a human CYP isoform involved in the metabolic activation of tegafur using human liver microsomes and cDNA-expressed human CYPs.

MATERIALS AND METHODS

Chemicals.
Tegafur and 5-chloro-2,4-dihydroxypyridine were obtained from Taiho Pharmaceutical Co. (Saitama, Japan). NADP+, glucose-6-phosphate and glucose-6-phosphate dehydrogenase, {alpha}-naphthoflavone, quinidine, sulfaphenazole, and troleandomycin were purchased from Sigma Chemical Co. (St. Louis, MO). Coumarin and p-nitrophenol were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Other chemicals were of the highest grade commercially available.

Enzymes and Antibodies.
Human liver microsomes were obtained from the International Institute for the Advancement of Medicine (Exton, PA) or SRI International (Menlo Park, CA). The human liver microsomes were diluted with 100 mM Tris-HCl buffer (pH 7.4) containing 1 mM DTT and 20% (v/v) glycerol and stored at -80°C until use. Microsomes prepared from human B-lymphoblastoid cells expressing CYP1A1 + OR, CYP1A2, CYP2A6 + OR, CYP2B6, CYP2C8 + OR, CYP2C9(Arg) + OR, CYP2C19, CYP2D6(Val) + OR, CYP2E1 + OR, and CYP3A4 + OR were obtained from Gentest (Woburn, MA). Control microsomes expressed only the vector. A monoclonal antibody against human CYP2A6 was obtained from Gentest.

Assay with Human Liver Microsomes.
The basic incubation mixture contained 0.5 mg/ml of human liver microsomes, 100 mM Tris-HCl buffer (pH 7.4), a NADPH-generating system (2 mM NADP+, 5 mM glucose-6-phosphate, 1 IU/ml of glucose-6-phosphate dehydrogenase, and 5 mM MgCl2), 0.4 mM 5-chloro-2,4-dihydroxypyridine, and 1 mM tegafur in a final volume of 250 or 500 µl. The mixture was incubated at 37°C for 10 min. After the reaction was stopped by acute freezing in acetone containing dry ice, the mixture was stored at -80°C until analysis. The formation of 5-FU was determined by gas chromatography/mass spectrometry (13) . Because 5-FU is extensively metabolized by a cytosolic protein, dihydropyridine dehydrogenase, the amount of 5-FU formed from tegafur in human liver microsomes is decreased by contaminated dihydropyridine dehydrogenase. Therefore, 0.4 mM 5-chloro-2,4-dihydroxypyridine was added in the incubation mixture as a potent inhibitor of dihydropyridine dehydrogenase (14) . This concentration of 5-chloro-2,4-dihydroxypyridine did not inhibit the marker activities of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A in human liver microsomes (data not shown).

Kinetic Studies.
Kinetic studies were performed using microsomes from four human livers (H-33, H-35m H-69, and HHM0071). In determining kinetic parameters, the tegafur concentration ranged from 0.5–20 mM. All reactions were performed in a linear range with respect to protein concentration and incubation time, 0.5 mg/ml microsomal protein and 10-min incubation time. Because tegafur is nonenzymatically converted to 5-FU, the content of 5-FU in the mixture incubated without microsomal protein was subtracted from that with microsomal protein to correct the activity. Eadie-Hofstee plots were constructed for determination of the presence of a mono- or biphasic model. Because reactions followed biphasic Michaelis-Menten kinetic behavior (i.e., two-enzyme kinetics), Michaelis-Menten kinetic parameters were estimated by fitting the data to the following equation (15) :

where V is the formation rate of 5-FU, S is the concentration of tegafur in the incubation mixture, Km1 and Km2 are the affinity constants for the high- and low-affinity components, respectively, and Vmax1 and Vmax2 are the maximum enzyme velocities for the high- and low-affinity components, respectively. Kinetic parameters were estimated initially by graphic analysis of Eadie-Hofstee plots, and the values were subsequently used as initial estimates for nonlinear regression analysis using a computer program (DeltaGraph program; Statistical Product and Service Solutions, Inc., Chicago, IL). When the data did not fit Eq. A, kinetic parameters of the reaction following biphasic Michaelis-Menten kinetic behavior were estimated by fitting the data to the following equation (16) :

where L represents the intrinsic clearance or Vmax/Km of low-affinity enzyme (i.e., Vmax2/Km2). Because reactions followed a simple Michaelis-Menten kinetic behavior (i.e., one-enzyme kinetics), the kinetic parameters (Km, Vmax, and Vmax/Km) of recombinant CYPs were estimated by nonlinear least-squares regression analysis.

Correlation Study.
Correlation between the formation rate of 5-FU at a 1-mM substrate concentration and 7-ethoxyresorufin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), 7-benzyloxyresorufin O-debenzylase (CYP2B6), tolbutamide methylhydroxylase (CYP2C9), S-mephenytoin 4'-hydroxylase (CYP2C19), dextromethorphan O-demethylase (CYP2D6), p-nitrophenol hydroxylase (CYP2E1), and testosterone 6ß-hydroxylase (CYP3A) activities were studied by using microsomes from 10 human livers. The isoform-specific activities were determined as described previously (17, 18, 19, 20, 21, 22, 23, 24, 25, 26) . The correlation coefficient (r) was calculated by the least-squares regression method using an SAS system for Windows (version 6.12; SAS Institute, Inc.).

Inhibition Study.
The effects of CYP isoform-specific inhibitors or substrates (i.e., compounds able to act as competitive inhibitors) on the formation of 5-FU at a 1 mM substrate concentration were investigated using microsomal preparations obtained from a human liver specimen (HHM-0071). The inhibitors used in this part of the study were {alpha}-naphthoflavone (a CYP1A2 inhibitor; Ref. 27 ), coumarin (a CYP2A6 substrate; Ref. 19 ), sulfaphenazole (a CYP2C8/9 inhibitor; Ref. 27 ), quinidine (a CYP2D6 inhibitor; Ref. 27 ), p-nitrophenol (a CYP2E1 inhibitor; Ref. 28 ), and troleandomycin (a CYP3A inhibitor; Ref. 27 ). The range of concentration used was 1–100 µM. Inhibitors were dissolved in DMSO and diluted with 100 mM Tris-HCl buffer (pH 7.4) so that the final concentration of solvent in the incubation mixture was 0.5%. The same concentration of DMSO was also added to the control. The incubation mixture, including chemical inhibitors, was preincubated for 5 min before the reaction was initiated by the addition of a substrate.

Inhibitory effects of antibodies to human CYP2A6 were examined by preincubating microsomes with the antibodies for 30 min on ice. Tegafur (1 mM) and other components of the incubation medium were then added, and the reaction was carried out as described above. The amounts of monoclonal antibodies against human CYP2A6 used were up to 0.8 µg/µg microsomal protein. This monoclonal antibody is a potent CYP2A6-specific inhibitor yielding 90% inhibition of human liver microsomal CYP2A6, whereas it does not inhibit human CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.4

Assay with Recombinant CYPs.
Microsomes from human B-lymphoblastoid cells expressing CYP1A1 (lot 19), CYP1A2 (lot 43), CYP2A6 (lot 26), CYP2B6 (lot 35), CYP2C8 (lot 13), CYP2C9 (lot 7), CYP2C19 (lot 9), CYP2D6 (lot 11), CYP2E1 (lot 26), and CYP3A4 (lot 31) were used. The reactions were carried out as described for the human liver microsomal study. To examine the role of individual CYP isoforms involved in the formation of 5-FU from tegafur, each of the recombinant CYPs (0.5 mg/ml) described above was incubated with 1 mM tegafur for 10 min at 37°C, according to the procedure recommended by the supplier.

Kinetic studies were performed using microsomes from human B-lymphoblastoid cells expressing CYP2A6 and CYP2C9. In determining kinetic parameters, the tegafur concentration ranged from 0.5 to 20 mM. All reactions were performed in a linear range with respect to protein concentration and incubation time, 0.5 mg/ml microsomal protein and 10-min incubation time. The kinetic parameters were estimated as described above.

RESULTS

Kinetics of 5-FU Formation from Tegafur in Human Liver Microsomes.
Eadie-Hofstee plots for the formation of 5-FU from tegafur (0.5–20 mM) in four human liver microsomes are shown in Fig. 2Citation . The plots showed biphasic curves, suggesting that the reaction showed multiple-enzyme kinetic behavior. Because the data obtained from three human liver microsomes (H-35, H-69, and HHM-0071) fitted Eq. A, the kinetic parameters for high- and low-affinity components were estimated. For a microsomal sample (H-33), the kinetic parameters for the high-affinity component were estimated by fitting the data to Eq. B. The kinetic parameters for the formation of 5-FU in four human liver microsomes are listed in Table 1Citation . The mean (± SD) kinetic parameters for the high-affinity component obtained from four human liver microsomes were: Km1 = 0.43 ± 0.05 mM, and Vmax1 = 4.02 ± 1.70 nmol/mg/min. The Vmax1/Km1 value was 88-fold greater that the Vmax2/Km2 value (9.74 ± 5.42 versus 0.11 ± 0.11 µl/mg/min).



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Eadie-Hofstee plots of 5-FU formation from tegafur in microsomal samples from four human livers (H-33, H-35, H-69, and HHM-0071). v, velocity of metabolite formation; s, substrate concentration. Tegafur (0.5–20 mM) was incubated at 37°C for 10 min with 0.5 mg/ml of human liver microsomes. Each data point represents the mean of duplicate experiments.

 

View this table:
[in this window]
[in a new window]

  		Table 1 %Kinetic parameters of 5-FU formation from tegafur in microsomes from four human livers

 
Correlation Study.
The formation rate of 5-FU from tegafur in human liver microsomes varied 40-fold (0.12–5.01 nmol/mg/min) with the median value of 1.01 nmol/min/mg among the 10 samples studied. The formation rate of 5-FU from tegafur and the CYP isoform-selective catalytic activity in the same panel of 10 human liver microsomes were compared. As shown in Fig. 3Citation , the formation rate of 5-FU in the 10 human liver microsome preparations at 1 mM tegafur was significantly correlated with coumarin 7-hydroxylase activity (r = 0.98; P < 0.001). No other significant correlations were observed between the formation rate of 5-FU and catalytic activities of 7-ethoxyresorufin O-deethylase (r = 0.38; P = 0.277), 7-benzyloxyresorufin O-debenzylase (r = 0.12; P = 0.747), tolbutamide methylhydroxylase (r = 0.52; P = 0.116), S-mephenytoin 4'-hydroxylase (r = 0.37; P = 0.297), dextromethorphan O-demethylase (r = 0.10; P = 0.783), p-nitrophenol hydroxylase (r = 0.41; P = 0.244), or testosterone 6ß-hydroxylase (r = 0.45; P = 0.200).



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Correlation between 5-FU formation and CYP2A6 activity in 10 human liver microsomes. The formation rates of 5-FU from tegafur in 10 human liver microsomes were compared with the coumarin 7-hydroxylase activity catalyzed by CYP2A6. Tegafur (1 mM) was incubated at 37°C for 10 min with 0.5 mg/ml of human liver microsomes. Coumarin (20 µM) was incubated at 37°C for 10 min with 0.4 mg/ml of human liver microsomes. The correlation coefficient (r) was calculated by the least-squares regression method.

 
Inhibition Study.
CYP isoform-specific xenobiotic compounds were screened for inhibitory effects on the formation of 5-FU from tegafur in human liver microsomes (Fig. 4)Citation . Coumarin, a specific substrate of CYP2A6, inhibited the formation of 5-FU in human liver microsomes in a concentration-dependent manner. The formation of 5-FU was inhibited by {alpha}-naphthoflavone and p-nitrophenol, whereas the extent of inhibition by these inhibitors was slight (<20%), even at a concentration of 100 µM. No effects of sulfaphenazole, quinidine, and troleandomycin were observed with inhibitor concentrations up to 100 µM.



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Effects of chemical inhibitors for CYPs on the formation of 5-FU from tegafur in human liver microsomes. Tegafur (1 mM) was incubated at 37°C for 10 min with 0.5 mg/ml of human liver microsomes (HHM-0071). Inhibitors were dissolved in DMSO and added to the incubation mixture at a final acetonitrile concentration of <5%. Human liver microsomes (0.5 mg/ml) were preincubated with various concentrations of inhibitors for 5 min at 37°C before the addition of a substrate. Data are expressed as percentages of the formation rate of 5-FU in the incubation mixture containing the same concentration of solvent without inhibitors. Each column represents the mean of three different experiments; bars, SD. *, P < 0.01; **, P < 0.001.

 
Similar results were obtained in the antibody inhibition study. As shown in Fig. 5Citation , anti-CYP2A6 antibodies showed 90% inhibition against the formation of 5-FU from tegafur at 0.8 µg/µg microsomal protein.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effects of anti-CYP2A6 antibodies on the formation of 5-FU from tegafur in human liver microsomes (HHM-0071). Human liver microsomes (0.5 mg/ml) were preincubated with various amounts of anti-CYP2A6 antibodies (0 to 0.8 mg/mg microsomal protein) for 30 min on ice. The incubation medium containing tegafur (1 mM) and other components were added to the mixture of microsomes and antibodies, and the reaction was carried out as described in "Materials and Methods." Data are expressed as percentages of the formation of 5-FU in the absence of antibodies. Each point represents the mean of three different experiments; bars, SD.

 
Study with cDNA-expressed CYPs.
Microsomes from human B-lymphoblastoid cells expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were examined in terms of the abilities of individual CYP proteins to catalyze the formation of 5-FU from tegafur. As shown in Fig. 6Citation , formation of 5-FU was found in cDNA-expressed CYP2A6 and CYP2C9 (7.14 and 1.67 pmol/pmol CYP/min, respectively). Other isoforms showed negligible activity for the formation of 5-FU from tegafur. Accordingly, kinetic analysis for the formation of 5-FU was performed using the microsomes from cDNA-expressed CYP2A6 and CYP2C9. Because Eadie-Hofstee plots for the formation of 5-FU in cDNA-expressed CYP2A6 and CYP2C9 were linear (data not shown), kinetic parameters were estimated by nonlinear least-squares regression analysis. The apparent Km of CYP2A6 (0.53 mM) was >20-fold lower than that of CYP2C9 (12 mM). The Vmax values of CYP2A6 and CYP2C9 were 38.54 and 1.56 pmol/pmol CYP/min, respectively. The cDNA-expressed CYP2A6 showed much greater values of Vmax/Km than did the cDNA-expressed CYP2C9 (72.4 versus 0.1 µl/nmol CYP/min).



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Formation rate of 5-FU from tegafur in microsomes from human B-lymphoblastoid cells expressing individual human CYPs. A substrate (1 mM tegafur) was incubated at 37°C for 10 min with microsomes (0.5 mg/ml) from human B-lymphoblastoid cells expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Each column represents the mean of three different experiments; bars, SD.

 
DISCUSSION

The results of the present study clearly showed that CYP2A6 is a principal enzyme responsible for the bioactivation process of tegafur in human liver microsomes. The supporting evidence can be summarized as follows: (a) the formation rate of 5-FU from tegafur in a panel of 10 human liver microsomes was significantly correlated with coumarin 7-hydroxylase activity, a marker activity of CYP2A6 (r = 0.98; P < 0.001; Fig. 3Citation ), but it was not correlated with other activities of CYPs; (b) coumarin, a specific substrate of CYP2A6, inhibited the formation of 5-FU in human liver microsomes in a concentration-dependent manner (Fig. 4)Citation ; (c) the anti-CYP2A6 antibody inhibited the formation of 5-FU by 90% in human liver microsomes (Fig. 5)Citation ; (d) cDNA-expressed CYP2A6 showed the highest activity for the formation of 5-FU among the 10 cDNA-expressed CYPs (Fig. 6)Citation with a Km similar to that found for the high-affinity component in human liver microsomes (Table 1)Citation . Although cDNA-expressed CYP2C9 showed the second-highest activity for the formation of 5-FU from tegafur (Fig. 6)Citation , it does not appear to contribute significantly to the bioactivation of tegafur in human liver microsomes, because the intrinsic clearance (Vmax/Km) for the formation of 5-FU from tegafur was much smaller than that of CYP2A6.

CYP2A6 is an enzyme showing genetic polymorphism (29) . To date, there have been four mutant alleles, designated as CYP2A6*2, *3, *4, and *5, in addition to the wild-type allele (CYP2A6*1; Ref. 30 ). CYP2A6*2 has a single base mutation (T->A), leading to a change from Leu-160 to His-160 in exon 3, which results in the formation of a catalytically inactive enzyme (31) . CYP2A6*3 has been proposed to be inactive, because it was formed by the gene conversion of CYP2A6*1 and functionally inactive CYP2A7 gene in exons 3, 6, and 8 (31) , although its functionality is not fully understood because of the low prevalence of homozygotes for this mutant allele. The gene frequencies of CYP2A6*2 are 1.1, 1.4, 3.0, and 2.3% in Swedes, Finns, Spaniards (32) , and Germans (33) , respectively, and that of CYP2A6*3 is 1.4% in Germans (33) , but they have not been detected in Japanese (34) . CYP2A6*4 is an allele with a partial or whole deletion of the CYP2A6 gene (35, 36, 37, 38) . Microsomes prepared from the liver of a homozygote for the gene deletion of CYP2A6 are devoid of CYP2A6 protein (29 , 35) . This type of mutant gene is relatively common in Oriental populations, with frequencies of 15.1% in Chinese (37) and 4.5% in Japanese (38) , whereas it is rare in Finns (1.0%) and Spaniards (0.5%; Ref. 37 ). CYP2A6*5 is a new defective allele, but it is rare in Chinese (1.0%) and has not been detected in Spaniards (30) .

These mutant alleles of CYP2A6 have been reported to be associated with decreased metabolic clearances of several drugs or environmental chemicals. For example, the metabolic clearance of SM-12502, a platelet-activating factor receptor antagonist, which is entirely metabolized by CYP2A6, was shown to be markedly decreased in subjects with a CYP2D6 gene deletion (36) . Similarly, the formation of cotinine from nicotine, which is predominantly catalyzed by CYP2A6, is dramatically decreased in homozygous subjects with a CYP2A6 gene deletion (39) . These findings coupled with the present observations suggest that bioactivation of tegafur is suppressed and that there is an insufficient level of 5-FU in the plasma or tumor of patients treated with tegafur/uracil or S-1 if they carry mutant alleles of CYP2A6. However, to what extent the bioactivation of tegafur by CYP2A6 accounts for the formation of 5-FU in vivo remains unclear, because the Km for the formation of 5-FU from tegafur obtained in the present study (i.e., 0.43 mM; Table 1Citation ) is higher than the plasma concentrations of tegafur (0.02–0.05 mM) after the repeated administration of tegafur/uracil to the patients, 300 mg/m2/day (40) . In addition, the formation of 5-FU from tegafur is also catalyzed by the soluble fraction of a 100,000 x g supernatant, and 5-FU is derived from spontaneous degradation of tegafur (41 , 42) . Therefore, further in vivo studies are clearly needed to clarify the influence of CYP2A6 polymorphism on the formation of 5-FU in patients taking tegafur/uracil or S-1.

Because few drugs are known to be metabolized by CYP2A6, there is limited information on drug interaction caused by the inhibition or induction of CYP2A6. Mäenpä et al. (43) reported that methoxalen, an antipsoriatic agent, inhibits the formation of 7-hydroxycoumarin from coumarin, the activity of which is the marker activity of CYP2A6 in vivo in human volunteers. Methoxalen was reported to be a mechanism-based inhibitor of CYP2A6 (44) . It was also reported that grapefruit juice flavonoids inhibit the formation of 7-hydroxycoumarin in healthy volunteers (45) . These findings suggest that the formation of 5-FU from tegafur may be suppressed by the concurrent administration of methoxalen or by taking tegafur with grapefruit juice. On the other hand, patients treated with antiepileptic drugs excrete all of the measurable 7-hydroxycoumarin in the first 4 h (46) , suggesting that CYP2A6 is inducible (29) . In accordance with the in vivo findings, an in vitro study using primary human hepatocytes indicated that CYP2A6 is induced by treatment with phenobarbital or rifampicin (29) . These findings suggest that the formation of 5-FU from tegafur is accelerated in patients treated with antiepileptic drugs or rifampicin.

In conclusion, the results of the present study clearly showed that CYP2A6 is a principal enzyme responsible for the bioactivation process of tegafur in human liver microsomes. This suggests that genetic polymorphism of CYP2A6 and/or drug interaction affect the formation of 5-FU from tegafur and modify the outcome of cancer chemotherapy using tegafur/uracil or S1, although further studies are clearly needed to confirm these possibilities.

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by Grant-in-Aid 1-7-1-C from the Japan Health Science Foundation. Back

2 To whom requests for reprints should be addressed, at Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263-8522, Japan. Phone/Fax: 81-43-290-2919; E-mail: kchiba{at}p.chiba-u.ac.jp Back

3 The abbreviations used are: 5-FU, 5-fluorouracil; CYP, cytochrome P-450; OR, NADPH cytochrome P-450 oxidoreductase. Back

4 Gentest (Woburn, MA), unpublished data. Back

Received 6/28/00; revised 8/29/00; accepted 8/31/00.

REFERENCES

  1. Hiller S. A., Zhuk R. A., Lidak M. Y. Analogs of pyrimidine nucleosides. I. N1-({alpha}-furanidyl) derivatives of natural pyrimidine bases and their antimetabolites. Dokl. Akad. Nauk Uzb. USSR, 176: 332-335, 1967.
  2. Diasio R. B. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs, 58(Suppl.3): 119-126, 1999.
  3. Hoff P. M., Lassere Y., Pazdur R. Tegafur/uracil + calcium folinate in colorectal cancer. Double modulation of fluorouracil. Drugs, 58(Suppl.3): 77-83, 1999.
  4. Takechi T., Nakano K., Uchida J., Mita A., Toko K., Takeda S., Unemi N., Shirasaka T. Antitumor activity and low intestinal toxicity of S-1, a new formation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol., 39: 205-211, 1997.[CrossRef][Medline]
  5. Ajani J. A., Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs, 58(Suppl.3): 85-90, 1999.
  6. Langer C. J. The role of tegafur/uracil in pulmonary malignancy. Drugs, 58(Suppl.3): 71-75, 1999.
  7. Brockstein B. E., Vokes E. E. Oral chemotherapy in head and neck cancer. Drugs, 58(Suppl.3): 91-97, 1999.
  8. El-Sayed Y. M., Sadee W. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Biochem. Pharmacol., 31: 3006-3008, 1982.[CrossRef][Medline]
  9. Meiren D. V., Belousova A. K. Mechanism of action of ftorafur, a new antineoplastic agent. Vopr. Med. Khim., 18: 288-293, 1972.[Medline]
  10. Fujita, H., and Kimura, K. In vivo distribution and metabolism of N-1-(tetrahydrofuran-2-yl)-5-fluorouracil (FT-207). In: G. K. Daikos (ed.), Progress in Chemotherapy (Antibacterial, Antiviral, Antineoplastic), Vol. 3. Proceedings of the VIII International Congress on Chemotherapy and Hellinic Society of Chemotherapy, pp. 159–164. Athens Hellinic Society for Chemotherapy, 1973.
  11. van der Weide J., Steijns L. S. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem., 36: 722-729, 1999.
  12. Lin J. H., Lu A. Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 35: 361-390, 1998.[CrossRef][Medline]
  13. Matsushima E., Yoshida K., Kitamura R., Yoshida K. E. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J. Chromatogr. B, 691: 95-104, 1997.
  14. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn. J. Cancer Res., 78: 748-755, 1987.[Medline]
  15. Kobayashi K., Nakajima M., Oshima K., Shimada N., Yokoi T., Chiba K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab. Dispos., 27: 860-865, 1999.[Abstract/Free Full Text]
  16. Brøsen K., Skjelbo E., Rasmussen B. B., Poulsen H. E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol., 45: 1211-1214, 1993.[CrossRef][Medline]
  17. Matsubara T., Otsubo S., Yoshihara E. Liver microsomal cytochrome P-450-dependent O-dealkylation reaction in various animals. Jpn. J. Pharmacol., 33: 1065-1075, 1983.[Medline]
  18. Greenlee W. F., Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Pharmacol. Exp. Ther., 205: 596-605, 1978.[Abstract/Free Full Text]
  19. Yun C-H., Shimada T., Guengerich F. P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol., 40: 679-685, 1991.[Abstract]
  20. Grant M. H., Duthie S. J., Gray A. G., Burke M. D. Mixed function oxidase and UDP-glucuronyltransferase activities in the human HEP G2 hepatoma cell line. Biochem. Pharmacol., 37: 4117-4120, 1988.[CrossRef][Medline]
  21. Miners J. O., Smith K. J., Robson R. A., MacManus M. E., Veronese M. E., Birkett D. J. Tolbutamide hydroxylation by human liver microsomes. Kinetics characterisation and relationship to other cytochrome P-450-dependent xenobiotic oxidations. Biochem. Pharmacol., 37: 1137-1144, 1988.[CrossRef][Medline]
  22. Relling M. V., Aoyama T., Gonzalez F. J., Meyer U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther., 252: 442-447, 1990.[Abstract/Free Full Text]
  23. Meier U. T., Kronbach T., Meyer U. S. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem., 151: 286-291, 1985.[CrossRef][Medline]
  24. Patten C. J., Ishizaki H., Aoyama T., Lee M., Ning S. M., Huang W., Gonzalez F. J., Yang C. S. Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells. Arch. Biochem. Biophys., 299: 163-171, 1992.[CrossRef][Medline]
  25. Kronbach T. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol., 206: 509-517, 1991.[Medline]
  26. Waxman D. J., Attisano C., Guengerich F. P., Lapenson D. P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6ß-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys., 263: 424-436, 1988.[CrossRef][Medline]
  27. Newton D. J., Wang R. W., Lu A. Y. H. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23: 154-158, 1995.[Abstract]
  28. Tassaneeyakul W., Veronese M. E., Birkett D. J., Gonzalez F. J., Miners J. O. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol., 46: 1975-1981, 1993.[CrossRef][Medline]
  29. Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology, 144: 139-147, 2000.[CrossRef][Medline]
  30. Oscarson M., McLellan R. A., Gullsten H., Agundez J. A., Benitez J., Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett., 460: 321-327, 1999.[CrossRef][Medline]
  31. Fernandez-Salguero P., Hoffman S. M., Cholerton S. M. G., Cholerton S., Mohrenweiser H., Rautio H., Pelkonen O., Huang J-D., Evans W. E., Idle J. R., Gonzalez F. D. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet., 57: 651-660, 1995.[Medline]
  32. Oscarson M., Gullsten H., Rautio A., Bernal M. L., Sinues B., Dahl M-L., Stengard J. H., Pelkonen O., Raunio H., Ingelman-Sundberg M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett., 438: 201-205, 1998.[CrossRef][Medline]
  33. Bourian M., Gullsten H., Legrum W. Genetic polymorphism of CYP2A6 in the German population. Toxicology, 144: 129-137, 2000.[CrossRef][Medline]
  34. Umematsu, Y., Yokoi, T., Nunoya, K. I., Takahashi, Y., Kinoshita, M., Shimada, T., and Kamataki, T. Improvement of genotyping method of CYP2A6 gene and allelic frequency in Japanese. Abstracts of the 118th Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, Vol. 3, p. 28. Tokyo: The Pharmaceutical Society of Japan, 1998.
  35. Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M., Kamataki T. A new deleted allele in human cytochrome P450 2A6 (CYP2A6) gene found in human liver subjects showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thialidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 8: 239-249, 1998.[Medline]
  36. Nunoya K., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thialidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther., 289: 437-442, 1999.[Abstract/Free Full Text]
  37. Oscarson M., McLellan R. A., Gullsten H., Yue Q-Y., Lang M., Bernal M. L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett., 448: 105-110, 1999.[CrossRef][Medline]
  38. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm. Res., 45: 517-524, 1998.
  39. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient cotinine formation from cotinine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther., 67: 57-69, 2000.[CrossRef][Medline]
  40. Pazdur R. Phase I and pharmacokinetic evaluation of UFT plus oral leucovorin. Oncology, 11(Suppl.10): 35-39, 1997.
  41. Wu A. T., Au J. L., Sadee W. Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res., 38: 210-214, 1978.[Abstract/Free Full Text]
  42. Au J. L., Sadee W. Activation of Ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and {gamma}-butyrolactone. Cancer Res., 40: 2814-2819, 1980.[Abstract/Free Full Text]
  43. Maenpaa J., Juvonen R., Raunio H., Rautio A., Pelkonen O. Methoxalen and coumarin interactions in man and mouse. Biochem. Pharmacol., 48: 1363-1369, 1994.[CrossRef][Medline]
  44. Koenigs L. L., Peter R. M., Thompson S. J., Rettie A. E., Trager W. F. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos., 25: 1407-1415, 1997.[Abstract/Free Full Text]
  45. Merkel U., Sigusch H., Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur. J. Clin. Pharmacol., 46: 175-177, 1994.[Medline]
  46. Sotaniemi E. A., Rautio A., Backstrom M., Arvela P., Pelkonen O. Hepatic cytochrome P450 isozyme (CYP2A6 and CYP3A4) activities and fibrotic process in liver. Br. J. Clin. Pharmacol., 39: 71-76, 1995.[Medline]



This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K. Fujita, H. Nakayama, W. Ichikawa, W. Yamamoto, H. Endo, F. Nagashima, R. Tanaka, T. Miya, Y. Sunakawa, K. Yamashita, et al.
Pharmacokinetics of 5-Fluorouracil in Elderly Japanese Patients with Cancer Treated with S-1 (a Combination of Tegafur and Dihydropyrimidine Dehydrogenase Inhibitor 5-Chloro-2,4-dihydroxypyridine)
Drug Metab. Dispos., July 1, 2009; 37(7): 1375 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fujita, W. Ichikawa, W. Yamamoto, H. Endo, F. Nagashima, R. Tanaka, T. Miya, K. Araki, K. Kodama, Y. Sunakawa, et al.
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas
Ann. Onc., May 1, 2009; 20(5): 946 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Shirasaka
Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 2 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod
Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?
Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Yokoo, A. Hamada, H. Watanabe, T. Matsuzaki, T. Imai, H. Fujimoto, K. Masa, T. Imai, and H. Saito
Involvement of Up-Regulation of Hepatic Breast Cancer Resistance Protein in Decreased Plasma Concentration of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Coadministration of S-1 in Rats
Drug Metab. Dispos., September 1, 2007; 35(9): 1511 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Ajani, J. Faust, K. Ikeda, J. C. Yao, H. Anbe, K. L. Carr, M. Houghton, and P. Urrea
Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma
J. Clin. Oncol., October 1, 2005; 23(28): 6957 - 6965.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, K.
Right arrow Articles by Kawaguchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, K.
Right arrow Articles by Kawaguchi, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online